First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine … – Markets Insider
|
First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine …
Markets Insider Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today the first administration in the Phase I clinical study in Acute … |
Seeking Alpha |
Buy Celyad And Get In On The CAR–T Space In Solid Tumors: Medicine’s Next Frontier
Seeking Alpha In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor – T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T–cells that express a specific tumor antigen … |
|
Stem cell agency faces leadership challenge
Capitol Weekly California’s 12-year-old stem cell research effort is expected to give away tens of millions of dollars in public this week, but its most important matters — issues that deal with its survival and future — likely will be discussed behind closed doors … |
|
Stem cell agency faces leadership challenge
Capitol Weekly California’s 12-year-old stem cell research effort is expected to give away tens of millions of dollars in public this week, but its most important matters — issues that deal with its survival and future — likely will be discussed behind closed doors … |